Magnesium for Migraine Prevention: Does the Evidence Support It?

Approximately 40-50 million Americans experience migraines—roughly one in seven adults dealing with debilitating headaches that can last 4-72 hours, accompanied by nausea, light sensitivity, and complete disruption of normal life. The economic burden exceeds $20 billion annually in direct medical costs and lost productivity. For individuals, that translates to missed workdays, canceled plans, relationships strained by unpredictability, and desperate searches for anything that might help.

While first-line prescription preventives like beta-blockers and topiramate cost $5-30 monthly, many patients can’t tolerate their side effects. The newer CGRP inhibitors that work for treatment-resistant patients cost $685-980 monthly. Topiramate causes cognitive impairment so pronounced that patients have nicknamed it “Stupamax.” Beta-blockers trigger crushing fatigue and can worsen depression. Valproate carries birth defect risks that make it dangerous for women of childbearing age. These medications work for some people, but many can’t tolerate the side effects or find them only partially effective.

There’s a cheaper, safer alternative that most migraine sufferers have never considered: magnesium. The VA/DoD Headache Clinical Practice Guideline recommends it. Multiple international headache guidelines recommend magnesium alongside prescription preventives. Yet walk into a neurologist’s office and you’ll likely walk out with a prescription pad, not a suggestion to try magnesium first. Continue reading for our recommended magnesium types and doses.

---

What the Clinical Trials Found

The landmark study came in 1996. Researchers at a German headache clinic recruited 81 people with diagnosed migraines and split them into two groups. One received 600mg of magnesium daily. The other got placebo pills. Neither group knew which they were taking. The trial ran for 12 weeks.

These weren’t people with occasional headaches. They met strict International Headache Society diagnostic criteria for migraine, dealing with recurring attacks severe enough to disrupt work, family obligations, and basic daily functioning. Some had tried multiple prescription preventives already.

The results were clear. The magnesium group experienced a 41.6% reduction in attack frequency compared to just 15.8% in the placebo group. Migraine days per month decreased. Attack severity dropped. Duration shortened. Perhaps most tellingly, people needed less acute medication to treat breakthrough headaches.

That single study might be dismissed as a one-off finding. But subsequent research consistently confirmed the pattern. A systematic review of 8 randomized controlled trials involving 568 participants found magnesium significantly reduced both migraine frequency and intensity.

The VA/DoD systematic review found magnesium reduced migraine frequency by 2.6 headaches per month after 12 weeks of treatment.

These aren’t laboratory values or biomarker changes. These are hard outcomes that directly impact quality of life—fewer days spent in darkened rooms, fewer missed work shifts, fewer disrupted family events.

---

How Magnesium Compares to Prescription Drugs

The most revealing comparison came from a study that tested magnesium directly against valproate sodium, a prescription medication commonly used for migraine prevention. Patients received either 500mg magnesium twice daily or 400mg valproate twice daily.

Both groups improved similarly. Headache frequency dropped from about 5 per month to roughly 3 per month in both groups. Magnesium delivered comparable results to a prescription drug that costs exponentially more and carries far greater side effect burden.

The VA/DoD examined this evidence systematically for their 2023 clinical practice guideline. They reviewed four randomized controlled trials involving 266 participants total. Their conclusion: oral magnesium reduced migraine frequency by 2.6 headaches per month after 12 weeks of treatment with 500-600mg daily. The guideline explicitly recommends magnesium for migraine prevention, noting that benefits outweigh risks in patients with normal kidney function.

A comprehensive review published in the European Journal of Nutrition examined the quality of evidence across dozens of magnesium health claims. Researchers applied rigorous GRADE methodology to assess strength of evidence. Magnesium for migraine prevention had among the strongest evidence of any magnesium health outcome.

This matters because most supplement claims collapse under rigorous scrutiny. Magnesium for migraines doesn’t. It holds up to the same evidence standards applied to prescription medications.

---

Why Magnesium Works for Migraines

Migraine isn’t just a bad headache. It’s a neurological event involving abnormal electrical waves across the brain, blood vessel dysfunction, and overexcited nerve cells firing inappropriately.

Magnesium sits at the intersection of these mechanisms. It blocks specific receptors in the brain that, when overactive, trigger the abnormal electrical activity characteristic of migraine. It regulates how neurotransmitters are released between nerve cells. It helps blood vessels maintain normal tone instead of constricting and dilating abnormally.

Multiple studies document that migraine patients have lower magnesium levels than healthy people—not just in blood tests, but in spinal fluid and inside cells where magnesium does its actual work. A study of women with migraine found significantly lower magnesium levels compared to women without migraines.

Data from the National Health and Nutrition Examination Survey tracked 3,626 adults ages 20-50 and found that meeting the recommended dietary allowance for magnesium was associated with 17% lower odds of migraine. People with the highest magnesium intake had 24% lower odds. Higher intake correlated with lower migraine risk, suggesting magnesium is actually protective rather than just coincidentally associated.

---

Who Benefits Most

Not everyone with migraines responds equally to magnesium. The evidence points to specific groups where the effect is most pronounced.

Women with menstrual migraines show particularly strong responses. Hormonal fluctuations during the menstrual cycle affect magnesium levels, and clinical trials have demonstrated clear benefits for preventing menstrual-associated attacks. For women whose migraines cluster predictably around their periods, magnesium offers targeted relief without the systemic effects of hormonal treatments or the cognitive side effects of other preventives.

Pregnant women face a difficult situation with migraines. Many prescription preventives are unsafe during pregnancy due to birth defect risks, yet pregnancy can worsen migraine frequency. Magnesium is one of the few evidence-based options considered safe during pregnancy, making it especially valuable for this population.

Patients who can’t tolerate prescription preventives have limited options. Beta-blockers cause fatigue and can worsen depression. Topiramate triggers brain fog, tingling sensations, and weight loss. Blood pressure medications used for migraine prevention carry sexual dysfunction and weight gain risks. Magnesium provides a validated alternative when these drugs fail or aren’t tolerated.

People with low dietary magnesium intake likely see greater benefit. While standard blood tests don’t reliably reflect magnesium stored inside cells, individuals with poor diet, digestive conditions that impair absorption, or medications that deplete magnesium (like proton pump inhibitors or diuretics) are more likely to respond robustly to supplementation.

---

Considerations

Reducing migraine frequency from 6 attacks per month to 3-4 represents substantial improvement, but it’s not elimination. People with chronic migraine (15+ headache days monthly) typically need combination approaches rather than magnesium alone.

The formulation question remains partially unresolved. Different studies used different magnesium forms—citrate, dicitrate, oxide—making it difficult to declare one definitively superior. Citrate and dicitrate absorb better than oxide in theory, yet magnesium oxide still showed clear benefits in trials, possibly because the doses were high enough to compensate for lower absorption. Long term benefits are unclear.

---

What About Side Effects?

The safety profile is magnesium’s major advantage over prescription alternatives. In the landmark 1996 trial, the most common side effect was diarrhea, affecting 19% of participants. Stomach irritation occurred in 5%. No serious adverse events were reported.

This stands in stark contrast to prescription preventives. Topiramate causes cognitive impairment, tingling sensations, weight loss, kidney stones, and severe birth defects. Beta-blockers trigger fatigue, slow heart rate, low blood pressure, depression, and sexual dysfunction. Valproate causes weight gain, tremor, hair loss, liver toxicity, and devastating birth defects. Tricyclic antidepressants cause dry mouth, constipation, urinary retention, and weight gain.

Magnesium toxicity is theoretically possible but requires massive doses exceeding 5,000mg daily—roughly 8-10 times the dose used in migraine trials. In patients with normal kidney function, excess magnesium is efficiently eliminated in urine.

Magnesium draws water into the intestines, potentially causing loose stools or diarrhea. Magnesium oxide tends to cause more digestive upset than citrate. Starting with lower doses and gradually increasing improves tolerance.

Patients with chronic kidney disease need medical supervision before supplementing magnesium. But for the vast majority of migraine sufferers with normal kidney function, magnesium’s safety margin is remarkably wide.

---

Assumes daily dosing based on research protocols.

---

---

The Bottom Line

Magnesium citrate at 500-600mg daily reduces migraine frequency by 2.6 headaches per month after 12 weeks based on systematic reviews of randomized controlled trials. The VA/DoD guideline recommends it for migraine prevention. Direct comparison with the prescription drug valproate showed comparable results at a fraction of the cost with dramatically fewer side effects. For someone having 8-10 migraines monthly, reducing frequency to 5-7 attacks represents meaningful improvement at roughly $20 for three months of treatment.

---

References

1. Cohen F, Brooks CV, Sun D, et al. Prevalence and Burden of Migraine in the United States: A Systematic Review. Headache. 2024;64(5):516-532. doi:10.1111/head.14709
2. Ashina M, Katsarava Z, Do TP, et al. Migraine: Epidemiology and Systems of Care. Lancet. 2021;397(10283):1485-1495. doi:10.1016/S0140-6736(20)32160-7
3. Dodick DW. Migraine. Lancet. 2018;391(10127):1315-1330. doi:10.1016/S0140-6736(18)30478-1
4. Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, et al. Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine. 2025;178(3):426-433. doi:10.7326/ANNALS-24-01052
5. Moreland P, Gaffney B, Lanham JS. Migraine Headache Prophylaxis. American Family Physician. 2025;111(5):443-450
6. Silberstein SD. Topiramate in Migraine Prevention: A 2016 Perspective. Headache. 2017;57(1):165-178. doi:10.1111/head.12997
7. VA/DoD Clinical Practice Guideline for the Management of Headache. Full Guideline PDF. Published September 2023
8. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of Migraine With Oral Magnesium: Results From a Prospective, Multi-Center, Placebo-Controlled and Double-Blind Randomized Study. Cephalalgia. 1996;16(4):257-63. doi:10.1046/j.1468-2982.1996.1604257.x
9. von Luckner A, Riederer F. Magnesium in Migraine Prophylaxis—Is There an Evidence-Based Rationale? A Systematic Review. Headache. 2018;58(2):199-209. doi:10.1111/head.13217
10. Veronese N, Demurtas J, Pesolillo G, et al. Magnesium and Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational and Intervention Studies. European Journal of Nutrition. 2020;59(1):263-272. doi:10.1007/s00394-019-01905-w
11. Dominguez LJ, Veronese N, Sabico S, et al. Magnesium and Migraine. Nutrients. 2025;17(4):725. doi:10.3390/nu17040725
12. Slavin M, Li H, Khatri M, Frankenfeld C. Dietary Magnesium and Migraine in Adults: A Cross-Sectional Analysis of the National Health and Nutrition Examination Survey 2001-2004. Headache. 2021;61(2):276-286. doi:10.1111/head.14065
13. Silberstein SD, Holland S, Freitag F, et al. Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults. Neurology. 2012;78(17):1337-45. doi:10.1212/WNL.0b013e3182535d20
14. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the Prophylaxis of Migraine—A Double-Blind Placebo-Controlled Study. Cephalalgia. 1996;16(6):436-40. doi:10.1046/j.1468-2982.1996.1606436.x
15. Maier JA, Pickering G, Giacomoni E, et al. Headaches and Magnesium: Mechanisms, Bioavailability, Therapeutic Efficacy and Potential Advantage of Magnesium Pidolate. Nutrients. 2020;12(9):E2660. doi:10.3390/nu12092660
16. Dolati S, Rikhtegar R, Mehdizadeh A, Yousefi M. The Role of Magnesium in Pathophysiology and Migraine Treatment. Biological Trace Element Research. 2020;196(2):375-383. doi:10.1007/s12011-019-01931-z
17. Food and Drug Administration. Topiramate Label. DailyMed. 2025
18. Bonafede M, Sapra S, Shah N, et al. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States. Headache. 2018;58(5):700-714. doi:10.1111/head.13275